Tau deletion reduces plaque‐associated BACE 1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease, BACE1 protease initiates the amyloidogenic processing of amyloid precursor protein (APP) that eventually results in synthesis of β-amyloid (Aβ) peptide. Aβ deposition in turn causes accumulation of BACE1 in plaque-associated dystrophic neurites, thereby potentiating progressive Aβ deposition once initiated. Since systemic pharmacological BACE inhibition causes adverse effects in humans, it is important to identify strategies that specifically normalize overt BACE1 activity around plaques. The microtubule-associated protein tau regulates axonal transport of proteins, and tau deletion rescues Aβ-induced transport deficits in vitro. In the current study, long-term in vivo two-photon microscopy and immunohistochemistry were performed in tau-deficient APPPS1 mice. Tau deletion reduced plaque-associated axonal pathology and BACE1 accumulation without affecting physiological BACE1 expression distant from plaques. Thereby, tau deletion effectively decelerated formation of new plaques and reduced plaque compactness. The data revealed that tau reinforces Aβ deposition, presumably by contributing to accumulation of BACE1 in plaque-associated dystrophies. Targeting tau-dependent mechanisms could become a suitable strategy to specifically reduce overt BACE1 activity around plaques, thereby avoiding adverse effects of systemic BACE inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“Previous studies have reported that tau deletion affects A b deposition neither in APP23 mice (Ittner et al , 2010) nor in another transgenic model overexpressing APP with familial AD mutations (Roberson et al , 2007).”
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“Previous studies have reported that tau deletion affects A b deposition neither in APP23 mice (Ittner et al , 2010) nor in another transgenic model overexpressing APP with familial AD mutations (Roberson et al , 2007).”
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“While it is widely recognized that A b accumulation triggers tau aggregation (Go¨tz et al , 2001; Lewis et al , 2001), it has remained controversial whether tau affects A b deposition vice versa.”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“While it is widely recognized that A b accumulation triggers tau aggregation (Go¨tz et al , 2001; Lewis et al , 2001), it has remained controversial whether tau affects A b deposition vice versa.”
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“…cleavage of the transmembrane amyloid precursor protein (APP) by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) (Hussain et al , 1999; Sinha et al , 1999; Vassar et al , 1999; Yan et al , 1999) and c -secretase complex (Shoji et al , 1992; De Strooper, 2003; Wolfe & Kopan, 2004).”
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438 · cited 1×
“…cleavage of the transmembrane amyloid precursor protein (APP) by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) (Hussain et al , 1999; Sinha et al , 1999; Vassar et al , 1999; Yan et al , 1999) and c -secretase complex (Shoji et al , 1992; De Strooper, 2003; Wolfe & Kopan, 2004).”
Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134 · cited 1×
“The microtubule-associated protein tau (Goedert et al , 1988) mediates A b -induced microtubule disassembly (King et al , 2006) and A b -induced anterograde axonal trafficking deficits in vitro (Vossel et al , 2010, 2015).”
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 2×
“Heterozygous APPPS1 mice (Radde et al , 2006) were crossed with tau-deficient (Tau (cid:1) / (cid:1) ) mice (Dawson et al , 2001) and homozygous VGLUT1 Venus knock-in mice (Herzog et al , 2011).”
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965
Tau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729 · cited 1×
“…, 2009; Deng et al , 2013; Kandalepas et al , 2013), which might be the reason for the twofold increased BACE1 levels in brains of AD mice and AD patients compared to healthy individuals (Fukumoto et al , 2002, 2004; Holsinger et al , 2002; Tyler et al , 2002; Yang et al , 2003; Li et al , 2004).”
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · cited 2×
“Systemic BACE inhibition causes dose-dependent adverse effects in mice and humans (Filser et al , 2015; Egan et al , 2018).”
He, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562 · cited 1×
“…, 2009; Deng et al , 2013; Kandalepas et al , 2013), which might be the reason for the twofold increased BACE1 levels in brains of AD mice and AD patients compared to healthy individuals (Fukumoto et al , 2002, 2004; Holsinger et al , 2002; Tyler et al , 2002; Yang et al , 2003; Li et al , 2004).”
Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527
Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, M., Berry, R., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4396-06.2007 · Cited by 365 · cited 8×
“In the AD brain, BACE1 accumulates in dystrophic axons around plaques (Zhao et al , 2007; Zhang et al , 2009; Deng et al , 2013; Kandalepas et al , 2013), which might be the reason for the twofold increased BACE1 levels in brains of AD mice and AD patients compared to healthy individuals (Fukumoto…”
InfluentialDepletion of GGA3 Stabilizes BACE and Enhances β-Secretase Activity
Tesco, G., Koh, Y. H., Kang, E. L., Cameron, A. N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S.-H., Zhong, Z., Shen, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.012 · Cited by 337 · cited 1×
“The degradation of BACE1 occurs via the lysosomal pathways and therefore depends on retrograde axonal transport to the cell body (Tesco et al , 2007; Kang et al , 2010).”
β-Secretase Activity Increases with Aging in Human, Monkey, and Mouse Brain
Fukumoto, H., Rosene, D. L., Moss, M. B., Raju, S., Hyman, B. T., & Irizarry, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63159-8 · Cited by 294 · cited 1×
“…, 2009; Deng et al , 2013; Kandalepas et al , 2013), which might be the reason for the twofold increased BACE1 levels in brains of AD mice and AD patients compared to healthy individuals (Fukumoto et al , 2002, 2004; Holsinger et al , 2002; Tyler et al , 2002; Yang et al , 2003; Li et al , 2004).”
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Kandalepas, P. C., Sadleir, K. R., Eimer, W. A., Zhao, J., Nicholson, D. A., & Vassar, R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1152-3 · Cited by 240 · cited 4×
“Since BACE1 is particularly enriched in mossy fiber terminals (Kandalepas et al , 2013), a general plaque-unrelated alteration of BACE1 expression should clearly manifest in the hippocampal stratum lucidum.”
InfluentialAβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level
Sadleir, K. R., Eimer, W. A., Cole, S. L., & Vassar, R. (2015) · Molecular Neurodegeneration · doi:10.1186/1750-1326-10-1 · Cited by 213 · cited 1×
“Increased A b deposition is likely caused by the presence of an estrogen response element in the Thy-1 promoter driving expression of APP and PS1 in these transgenic mice (Sadleir et al , 2015).”
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177 · cited 2×
“Thus, an adequate BACE inhibitor dosage that sufficiently suppresses A b production at plaques might already cause excessive inhibition of physiological BACE1 and BACE2 function elsewhere in the body.”
Self-citationTau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β
Vossel, K. A., Xu, J. C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J. A., Ho, K., Kim, D. H., Yu, G.-Q., & Mucke, L. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201407065 · Cited by 167 · cited 3×
“These results are consistent with observations that ablating or knocking down tau in neurons prevented A b -induced axonal transport defects without affecting transport at baseline (Vossel et al , 2010, 2015).”
Leroy, K., Ando, K., Laporte, V., Dedecker, R., Suain, V., Authelet, M., Héraud, C., Pierrot, N., Yilmaz, Z., Octave, J.-N., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.012 · Cited by 161
Ubiquitin Regulates GGA3-mediated Degradation of BACE1
Kang, E. L., Cameron, A. N., Piazza, F., Walker, K. R., & Tesco, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.092742 · Cited by 111 · cited 1×
“The degradation of BACE1 occurs via the lysosomal pathways and therefore depends on retrograde axonal transport to the cell body (Tesco et al , 2007; Kang et al , 2010).”
In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques
Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B., & Herms, J. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-30 · Cited by 59
Self-citation
Cited by
Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
Villegas, S., Roda, A., Serra-Mir, G., Montoliu-Gaya, L., & Tiessler, L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.332127 · Cited by 306
Persistent repression of tau in the brain using engineered zinc finger protein transcription factors
Wegmann, S., DeVos, S. L., Zeitler, B., Marlen, K., Bennett, R. E., Perez-Rando, M., MacKenzie, D., Yu, Q., Commins, C., Bannon, R. N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1611 · Cited by 77
“Therefore, we tested whether endogenous tau repression in the adult brain using ZFP-TFs could reduce these early pathological changes, which seem to be, at least partially, caused by endogenous tau in the context of A production and deposition in mice (7, 36).”
BackgroundInfluentialJordà‐Siquier, T., Petrel, M., Kouskoff, V., Smailovic, U., Cordelières, F., Frykman, S., Müller, U., Mulle, C., & Barthet, G. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12546 · Cited by 63
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Metadata
- Authors
- Peters, F., Salihoglu, H., Pratsch, K., Herzog, E., Pigoni, M., Sgobio, C., Lichtenthaler, S. F., Neumann, U., & Herms, J.
- Venue
- The EMBO Journal
- Published
- 2019-11-07
- Volume
- 38
- Issue
- 23
- Pages
- e102345-e102345
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W2983578800
- Cited by
- 44
- References
- 30
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.